Jwk001

Phase 2

Jwk001 is one of 5 therapeutic programs targeting Neovascular Age-Related Macular Degeneration (nAMD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Neovascular Age-Related Macular Degeneration (namd)Recruiting

Neovascular Age-Related Macular Degeneration (namd)Phase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Neovascular Age-Related Macular Degeneration (namd)

#DrugCompanyPhaseTrials

Vabysmo

Roche

Approved

1 2

Eylea

Regeneron

Phase 3

5 3

Lucentis

Roche

Phase 3

2 4

OTX-TKI

OOcular Therapeutix, Inc.

Phase 3

1 5

Jwk001

WWest China Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Neovascular Age-Related Macular Degeneration (namd)

NCT07776522

Clinical

Trials by Indication[1]

Neovascular Age-Related Macular Degeneration (nAMD)1 trial

A Phase II Study to Evaluate the Safety and Preliminary Efficacy of Subretinal Administration of JWK001 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting·WWest China Hospital·Phase 2·NCT07776522·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Jwk001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Jwk001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: WWest China Hospital

Jwk001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Neovascular Age-Related Macular Degeneration (nAMD)1 trial

References

Drug Info

Quick Facts

Related News